Cultured Meat Innovation Consultancy

As the field of cultured meat continues to evolve, ensuring that your products meet regulatory standards and safety requirements is crucial for success. Our Cultured Meat Innovation Consultancy offers specialized support to guide you through the complexities of cell culture technology and regulatory compliance for cultured meat products.

We provide comprehensive expertise in Cell Culture for Meat, helping you develop and optimize your cell lines for efficient and scalable production. Our consultancy includes detailed Donor Animal Risk Assessments, evaluating factors such as geographical origin, veterinary surveillance, and zoonosis risks. We also support Cell Bank Testing, tailoring our testing panels to the specific technology used in cell line generation, and addressing risks associated with raw materials and reagents such as animal-derived serums.

Our services include comprehensive TSE (Transmissible Spongiform Encephalopathy) Risk Assessments and General Virus Safety Risk Assessments to ensure that your cultured meat products are safe and compliant with industry standards. We also address Sterility and Mycoplasma Testing to maintain the highest quality control throughout your production processes.

Partner with us to navigate the innovative landscape of cultured meat, ensuring that your products are both pioneering and compliant. Our expertise will support you in achieving regulatory approvals and advancing your technology with confidence.

Dr Andy Bailey

Managing Director & CEO

Andy, originally a chemist/biochemist, later specialized in virology during his 9-year tenure at the MRC Virology Unit in Glasgow, Scotland, where he focused on studying Herpesviruses and Adenoviruses. In 1995, he transitioned to the industry, first as Director of Virus Validation Services at Q-One Biotech Ltd, and later as part of the Pathogen Safety group of Baxter Healthcare in Vienna, Austria.

With over 30 years of expertise in virus and prion safety, Andy has presented at numerous regulatory agencies and conferences, supporting product registrations, and contributing as an invited speaker at expert workshops. His experience includes presentations to regulatory bodies to support submissions for various products, including the UK MHRA, German PEI, French AFFSAPS, US FDA, EMEA, and Japan´s PMDA. This deep involvement has given him a comprehensive understanding of regulatory affairs surrounding virus and prion safety.

Additionally, Andy served as an external expert for the EU SCENIHR committee on emerging human health risks, coauthoring an opinion on “The Safety of Human-derived Products with regard to Variant Creutzfeldt-Jakob Disease”. His ongoing contributions as a speaker at international biopharmaceutical conferences further reinforce his expertise and leadership in the field.

In 2005, Andy founded ViruSure, driven by a commitment to delivering reliable, high-quality testing services to the biopharmaceutical industry, a philosophy that remains a key focal point to the company today. This deep-rooted expertise ensures clients receive trusted, scientifically grounded consultancy, making ViruSure a dependable partner for biopharmaceutical safety needs.